


In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

In the claims:

1-90. (Canceled)

91. (Currently Amended) A compound having the general formula I:



Formula I

wherein:

n is an integer of 1-6, whereas if n=1, C_n, B_n, R_n, ~~R'_n~~ and Y are absent;

each of B₁, B₂, ...B_{n-1} and B_n is independently selected from the group consisting of oxygen, sulfur, nitrogen, ~~phosphorus~~phosphor and silicon, whereby each of said nitrogen, ~~phosphorus~~phosphor and silicon is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;


In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

each of A_1, A_2, \dots, A_{n-1} and A_n is independently selected from the group consisting of $CR''R'''$, $C=O$ and $C=S$, whereas when $n=3$, ~~at least one of A_1 and A_2~~ is $CR''R'''$;

Y is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biphosphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine and phosphoglycerol~~phosphoglycerol~~; and

each of X_1, X_2, \dots, X_{n-1} is independently a saturated or unsaturated hydrocarbon having the general formula II:




Formula II

wherein:

m is an integer of 1-26; and

Z is selected from the group consisting of:




whereas:

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

W is selected from the group consisting of oxygen, sulfur, nitrogen and ~~phosphorus~~~~phosphor~~, whereby each of said nitrogen and ~~phosphorus~~~~phosphor~~ is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo; and
 in at least one of X_1, X_2, \dots, X_{n-1} Z is not hydrogen, wherein if $n=3$, X_2 comprises a Z selected from the group consisting of:



and wherein:

each of $R_1, R'_1, R_2, \dots, R_{n-1}, R_n, R'_n$, each of R'' and R''' and each of $R_a, R'_a, R_b, R'_b, \dots, R_{m-1}, R'_{m-1}, R_m$ and R'_m is independently selected from the group consisting of hydrogen, a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of $R_1, R'_1, R_2, \dots, R_{n-1}, R_n$ and R'_n and/or at least two of $R_a, R'_a, R_b, R'_b, \dots, R_{m-1}, R'_{m-1}, R_m$ and R'_m form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring; and

each of $C_1, C_2, \dots, C_{n-1}, C_n$, and each of C_a, C_b, \dots, C_{m-1} and C_m is a chiral or non-chiral carbon atom, whereby each chiral carbon atom has a S-configuration and/or a R-configuration,

a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate thereof.

92. (Previously Presented) The compound of claim 91, wherein at least one of A_1, A_2, \dots and A_{n-1} is $CR''R'''$.



In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

93. (Previously Presented) The compound of claim 92 wherein at least one of said at least one of A_1 , A_2 , ... and A_{n-1} is linked to a X_1 , X_2 ... or X_{n-1} which comprises a Z different than hydrogen.

94-97. (Canceled)

98. (Currently Amended) The compound of claim ~~91~~⁹⁷, wherein n equals

3, and said X_2 comprises a Z is-selected from the group consisting of  and  and

99. (Previously Presented) The compound of claim 98, wherein W is oxygen and each of R'' and R''' is independently selected from the group consisting of hydrogen and alkyl.

100. (Previously Presented) The compound of claim 91, wherein n equals 1.

101. (Previously Presented) The compound of claim 100, wherein at least one of R_1 and R'_1 is a phosphate or a phosphonate.

102. (Previously Presented) The compound of claim 91, wherein n equals 5 or 6 and at least one of R_1 , R'_1 and at least one of R_n and R'_n form at least one heteroalicyclic ring.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

103. (Previously Presented) The compound of claim 102, wherein said at least one heteroalicyclic ring is a monosaccharide ring.

104. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the compound of claim 91 and a pharmaceutically acceptable carrier.

105. (Previously Presented) The pharmaceutical composition of claim 104, packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment or prevention of an inflammation associated with an endogenous oxidized lipid.

106. (Previously Presented) The pharmaceutical composition of claim 105, wherein said inflammation is associated with a disease or disorder selected from the group consisting of an idiopathic inflammatory disease or disorder, a chronic inflammatory disease or disorder, an acute inflammatory disease or disorder, an autoimmune disease or disorder, an infectious disease or disorder, an inflammatory malignant disease or disorder, an inflammatory transplantation-related disease or disorder, an inflammatory degenerative disease or disorder, a disease or disorder associated with a hypersensitivity, an inflammatory cardiovascular disease or disorder, an inflammatory cerebrovascular disease or disorder, a peripheral vascular disease or disorder, an inflammatory glandular disease or disorder, an inflammatory gastrointestinal disease or disorder, an inflammatory cutaneous disease or disorder, an inflammatory hepatic disease or disorder, an inflammatory neurological disease or disorder, an inflammatory musculo-skeletal disease or disorder, an inflammatory renal disease or disorder, an inflammatory reproductive disease or disorder, an inflammatory systemic disease or disorder, an inflammatory connective tissue disease or disorder, an inflammatory tumor, necrosis, an inflammatory implant-related disease

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

or disorder, an inflammatory aging process, an immunodeficiency disease or disorder, a proliferative disease or disorder and an inflammatory pulmonary disease or disorder.

107. (Previously Presented) The pharmaceutical composition of claim 106, wherein said hypersensitivity is selected from the group consisting of Type I hypersensitivity, Type II hypersensitivity, Type III hypersensitivity, Type IV hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity, immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity, delayed type hypersensitivity, helper T lymphocyte mediated hypersensitivity, cytotoxic T lymphocyte mediated hypersensitivity, TH1 lymphocyte mediated hypersensitivity, and TH2 lymphocyte mediated hypersensitivity.

108. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory cardiovascular disease or disorder is selected from the group consisting of an occlusive disease or disorder, atherosclerosis, a cardiac valvular disease, stenosis, restenosis, in-stent-stenosis, myocardial infarction, coronary arterial disease, acute coronary syndromes, congestive heart failure, angina pectoris, myocardial ischemia, thrombosis, Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome, anti-factor VIII autoimmune disease or disorder, necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis, antiphospholipid syndrome, antibody induced heart failure, thrombocytopenic purpura, autoimmune hemolytic anemia, cardiac autoimmunity, Chagas' disease or disorder, and anti-helper T lymphocyte autoimmunity.

109. (Previously Presented) The pharmaceutical composition of claim 106, wherein said cerebrovascular disease or disorder is selected from the group consisting of stroke, cerebrovascular inflammation, cerebral hemorrhage and vertebral arterial insufficiency.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

110. (Previously Presented) The pharmaceutical composition of claim 106, wherein said peripheral vascular disease or disorder is selected from the group consisting of gangrene, diabetic vasculopathy, ischemic bowel disease, thrombosis, diabetic retinopathy and diabetic nephropathy.

111. (Previously Presented) The pharmaceutical composition of claim 106, wherein said autoimmune disease or disorder is selected from the group consisting of chronic rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Bechet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides and heparin induced thrombocytopenia.

112. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory glandular disease or disorder is selected from the group consisting of pancreatic disease or disorder, Type I diabetes, thyroid disease or disorder, Graves' disease or disorder, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome.

113. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory gastrointestinal disease or disorder is selected from the group consisting of colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

disease, ulcerative colitis, an ulcer, a skin ulcer, a bed sore, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer and a gastrointestinal ulcer.

114. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory cutaneous disease or disorder is selected from the group consisting of acne, autoimmune bullous skin disease or disorder, pemphigus vulgaris, bullous pemphigoid, pemphigus foliaceus, contact dermatitis and drug eruption.

115. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory hepatic disease or disorder is selected from the group consisting of autoimmune hepatitis, hepatic cirrhosis, and biliary cirrhosis.

116. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory neurological disease or disorder is selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, myasthenia gravis, motor neuropathy, Guillain-Barre syndrome, autoimmune neuropathy, Lambert-Eaton myasthenic syndrome, paraneoplastic neurological disease or disorder, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, progressive cerebellar atrophy, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, autoimmune polyendocrinopathy, dysimmune neuropathy, acquired neuromyotonia, arthrogryposis multiplex, Huntington's disease, AIDS associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis, stroke, an inflammatory retinal disease or disorder, an inflammatory ocular disease or disorder, optic neuritis, spongiform encephalopathy, migraine, headache, cluster headache, and stiff-man syndrome.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

117. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory connective tissue disease or disorder is selected from the group consisting of autoimmune myositis, primary Sjogren's syndrome, smooth muscle autoimmune disease or disorder, myositis, tendinitis, a ligament inflammation, chondritis, a joint inflammation, a synovial inflammation, carpal tunnel syndrome, arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, a skeletal inflammation, an autoimmune ear disease or disorder, and an autoimmune disease or disorder of the inner ear.

118. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory renal disease or disorder is autoimmune interstitial nephritis and/or renal cancer.

119. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory reproductive disease or disorder is repeated fetal loss, ovarian cyst, or a menstruation associated disease or disorder.

120. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory systemic disease or disorder is selected from the group consisting of systemic lupus erythematosus, systemic sclerosis, septic shock, toxic shock syndrome, and cachexia.

121. (Previously Presented) The pharmaceutical composition of claim 106, wherein said infectious disease or disorder is selected from the group consisting of a chronic infectious disease or disorder, a subacute infectious disease or disorder, an acute infectious disease or disorder, a viral disease or disorder, a bacterial disease or disorder, a protozoan disease or disorder, a parasitic disease or disorder, a fungal disease or disorder, a mycoplasma disease or disorder, gangrene, sepsis, a prion

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

disease or disorder, influenza, tuberculosis, malaria, acquired immunodeficiency syndrome, and severe acute respiratory syndrome.

122. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory transplantation-related disease or disorder is selected from the group consisting of graft rejection, chronic graft rejection, subacute graft rejection, acute graft rejection hyperacute graft rejection, and graft versus host disease or disorder.

123. (Previously Presented) The pharmaceutical composition of claim 122, wherein said implant is selected from the group consisting of a prosthetic implant, a breast implant, a silicone implant, a dental implant, a penile implant, a cardiac implant, an artificial joint, a bone fracture repair device, a bone replacement implant, a drug delivery implant, a catheter, a pacemaker, an artificial heart, an artificial heart valve, a drug release implant, an electrode, and a respirator tube.

124. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory tumor is selected from the group consisting of a malignant tumor, a benign tumor, a solid tumor, a metastatic tumor and a non-solid tumor.

125. (Previously Presented) The pharmaceutical composition of claim 106, wherein said inflammatory pulmonary disease or disorder is selected from the group consisting of asthma, allergic asthma, emphysema, chronic obstructive pulmonary disease or disorder, sarcoidosis and bronchitis.

126. (Previously Presented) The pharmaceutical composition of claim 104, further comprising at least one additional compound capable of treating or preventing an inflammation associated with an oxidized lipid.

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

127. (Previously Presented) The pharmaceutical composition of claim 126, wherein said at least one additional compound is selected from the group consisting of a HMGCoA reductase inhibitor (a statin), a mucosal adjuvant, a corticosteroid, a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, an analgesic, a growth factor, a toxin, a HSP, a Beta-2-glycoprotein I, a cholesteryl ester transfer protein (CETP) inhibitor, a perioxosome proliferative activated receptor (PPAR) agonist, an anti-atherosclerosis drug, an anti-proliferative agent, ezetimide, nicotinic acid, a squalen inhibitor, an ApoE Milano, and any derivative and analog thereof.

128. (Currently Amended) The pharmaceutical composition of claim 10414, wherein at least one of A_1, A_2, \dots and A_{n-1} is $CR''R'''$.

129. (Previously Presented) The pharmaceutical composition of claim 128, wherein at least one of said at least one of A_1, A_2, \dots and A_{n-1} is linked to a X_1, X_2, \dots or X_{n-1} which comprises a Z different than hydrogen.

130-133. (Canceled)

134. (Currently Amended) The pharmaceutical composition of claim 104133, wherein n equals 3, and said X_2 comprises a Z ~~is~~ selected from the group

consisting of $\begin{array}{c} \text{OR}^* \\ | \\ \text{W}=\text{C} \\ | \end{array}$ and $\begin{array}{c} \text{WR}^* \\ | \\ -\text{CH} \\ | \\ \text{WR}'' \end{array}$.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

135. (Previously Presented) The pharmaceutical composition of claim 134, wherein W is oxygen and each of R'' and R''' is independently selected from the group consisting of hydrogen and alkyl.

136. (Previously Presented) The pharmaceutical composition of claim 104, wherein n equals 1.

137. (Previously Presented) The pharmaceutical composition of claim 136, wherein at least one of R₁ and R'₁ is a phosphate or a phosphonate.


138. (Previously Presented) The pharmaceutical composition of claim 104, wherein n equals 5 or 6 and at least one of R₁, R'₁ and at least one of R_n and R'_n form at least one heteroalicyclic ring.

139. (Previously Presented) The pharmaceutical composition of claim 138, wherein said at least one heteroalicyclic ring is a monosaccharide ring.

140. (Currently Amended) A method of treating ~~or preventing~~ an inflammation associated with an endogenous oxidized lipid, the method comprising administering to a subject in need thereof a therapeutically effective amount of at least one oxidized lipid of the general formula I:

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510



Formula I

wherein:

n is an integer of 1-6, whereas if n=1, C_n, B_n, R_n, and Y are absent;

each of B₁, B₂, ...B_{n-1} and B_n is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, whereby each of said nitrogen, phosphorus and silicon is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;

each of A₁, A₂, ...A_{n-1} and A_n is independently selected from the group consisting of CR''R''', C=O and C=S,


Y is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biphosphonate,

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine and phosphoglycerol; and

each of X_1, X_2, \dots, X_{n-1} is independently a saturated or unsaturated hydrocarbon having the general formula II:




Formula II

wherein:

m is an integer of 1-26; and

Z is selected from the group consisting of:



whereas W is selected from the group consisting of oxygen, sulfur, nitrogen and phosphorus, whereby each of said nitrogen and phosphorus is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo; and

at least one of X_1, X_2, \dots, X_{n-1} comprises a Z different than hydrogen and wherein:

each of $R_1, R'_1, R_2, \dots, R_{n-1}, R_n, R'_n$, each of R'' and R''' and each of Ra, R'a, Rb, R'b, $\dots, R_{m-1}, R'_{m-1}, R_m$ and R'm is independently selected from the group consisting of hydrogen, a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of R₁, R'₁, R₂, ... R_{n-1}, R_n and R'_n and/or at least two of R_a, R'_a, R_b, R'_b, ... R_{m-1}, R'_{m-1}, R_m and R'_m form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring; and

each of C₁, C₂, ..., C_{n-1}, C_n, and each of C_a, C_b, ... C_{m-1} and C_m is a chiral or non-chiral carbon atom, whereby each chiral carbon atom has a S-configuration and/or a R-configuration,

a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate thereof, thereby treating ~~or preventing~~ the inflammatory disease or disorder associated with an endogenous oxidized lipid in said subject.

141-142. (Canceled)

143. (Currently Amended) The method of claim ~~140~~142, wherein at least one of A₁, A₂, ... and A_{n-1} is CR''R'''.

144. (Previously Presented) The method of claim 143, wherein at least one of said at least one of A₁, A₂, ... and A_{n-1} is linked to a X₁, X₂ ... or X_{n-1} which comprises a Z different than hydrogen.

145. (Currently Amended) The method of claim ~~140~~142, wherein n equals 3.

146. (Previously Presented) The method of claim 145, wherein at least one of A₁ and A₂ is CR''R'''.

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

147. (Previously Presented) The method of claim 146, wherein A_2 is $CR''R'''$.

148. (Previously Presented) The method of claim 146, wherein each of A_1 and A_2 is $CR''R'''$.

149. (Previously Presented) The method of claim 145, wherein X_2 comprises a Z different than hydrogen.

150. (Previously Presented) The method of claim 149, wherein said Z is selected from the group consisting of $\begin{array}{c} \text{OR}'' \\ | \\ \text{W}=\text{C} \\ | \end{array}$ and $\begin{array}{c} \text{WR}'' \\ | \\ -\text{CH} \\ | \\ \text{WR}''' \end{array}$.

151. (Previously Presented) The method of claim 150, wherein W is oxygen and each of R'' and R''' is independently selected from the group consisting of hydrogen and alkyl.

152. (Currently Amended) The method of claim ~~140~~142, wherein n equals 1.

153. (Previously Presented) The method of claim 152, wherein at least one of R_1 and R'_1 is a phosphate or a phosphonate.

154. (Currently Amended) The method of claim ~~140~~142, wherein n equals 5 or 6, and at least one of R_1 , R'_1 and at least one of R_n and R'_n form at least one heteroalicyclic ring.

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

155. (Previously Presented) The method of claim 154, wherein said at least one heteroalicyclic ring is a monosaccharide ring.

156. (Currently Amended) The method of claim ~~140~~142, wherein said oxidized lipid is selected from the group consisting of: 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine, 1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC), 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), 1-palmitoyl-2-(9-oxononanooyl)-sn-glycero-3-phosphocholine, 1-hexadecyl-2-acetoyle- sn-glycero-3-phosphocholine, 1-octadecyl-2-acetoyle-sn-glycero-3-phosphocholine, 1-hexadecyl-2-butyroyle-sn-glycero-3-phosphocholine, 1-octadecyl-2-butyroyle-sn-glycero-3-phosphocholine, 1-palmitoyl-2-acetoyle-sn-glycero-3-phosphocholine, 1-octadecenyle-2-acetoyle-sn-glycero-3-phosphocholine, 1-hexadecyl-2-(homogammalinolenoyl)-sn-glycero-3-phosphocholine, 1-hexadecyl-2-arachidonoyl-sn-glycero-3-phosphocholine, 1-hexadecyl-2-eicosapentaenoyl-sn-glycero-3-phosphocholine, 1-hexadecyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, 1-octadecyl-2-methyle-sn-glycero-3-phosphocholine, 1-hexadecyl-2-butenoyl-sn-glycero-3-phosphocholine, Lyso PAF C16, Lyso PAF C18, 1-O-1'-(Z)-hexadecenyle-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-glycero-3-phosphocholine, 1-O-1'-(Z)-hexadecenyle-2-oleoyl-sn-glycero-3-phosphocholine, 1-O-1'-(Z)-hexadecenyle-2-arachidonoyl-sn-glycero-3-phosphocholine, 1-O-1'-(Z)-hexadecenyle-2-docosahexaenoyl-sn-glycero-3-phosphocholine, 1-O-1'-(Z)-hexadecenyle-2-oleoyl-sn-glycero-3-phosphoethanolamine, 1-O-1'-(Z)-hexadecenyle-2-arachidonoyl-sn-glycero-3-phosphoethanolamine, and 1-O-1'-(Z)-hexadecenyle-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine.

157. (Previously Presented) The method of claim 140, wherein said inflammation is associated with a disease or disorder selected from the group

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

consisting of an idiopathic inflammatory disease or disorder, a chronic inflammatory disease or disorder, an acute inflammatory disease or disorder, an autoimmune disease or disorder, an infectious disease or disorder, an inflammatory malignant disease or disorder, an inflammatory transplantation-related disease or disorder, an inflammatory degenerative disease or disorder, a disease or disorder associated with a hypersensitivity, an inflammatory cardiovascular disease or disorder, an inflammatory cerebrovascular disease or disorder, a peripheral vascular disease or disorder, an inflammatory glandular disease or disorder, an inflammatory gastrointestinal disease or disorder, an inflammatory cutaneous disease or disorder, an inflammatory hepatic disease or disorder, an inflammatory neurological disease or disorder, an inflammatory musculo-skeletal disease or disorder, an inflammatory renal disease or disorder, an inflammatory reproductive disease or disorder, an inflammatory systemic disease or disorder, an inflammatory connective tissue disease or disorder, an inflammatory tumor, necrosis, an inflammatory implant-related disease or disorder, an inflammatory aging process, an immunodeficiency disease or disorder and an inflammatory pulmonary disease or disorder.

158. (Previously Presented) The method of claim 157, wherein said hypersensitivity is selected from the group consisting of Type I hypersensitivity, Type II hypersensitivity, Type III hypersensitivity, Type IV hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity, immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity, delayed type hypersensitivity, helper T lymphocyte mediated hypersensitivity, cytotoxic T lymphocyte mediated hypersensitivity, TH1 lymphocyte mediated hypersensitivity, and TH2 lymphocyte mediated hypersensitivity.

159. (Previously Presented) The method of claim 157, wherein said inflammatory cardiovascular disease or disorder is selected from the group consisting

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

of an occlusive disease or disorder, atherosclerosis, a cardiac valvular disease, stenosis, restenosis, in-stent-stenosis, myocardial infarction, coronary arterial disease, acute coronary syndromes, congestive heart failure, angina pectoris, myocardial ischemia, thrombosis, Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome, anti-factor VIII autoimmune disease or disorder, necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis, antiphospholipid syndrome, antibody induced heart failure, thrombocytopenic purpura, autoimmune hemolytic anemia, cardiac autoimmunity, Chagas' disease or disorder, and anti-helper T lymphocyte autoimmunity.

160. (Previously Presented) The method of claim 157, wherein said cerebrovascular disease or disorder is selected from the group consisting of stroke, cerebrovascular inflammation, cerebral hemorrhage and vertebral arterial insufficiency.

161. (Previously Presented) The method of claim 157, wherein said peripheral vascular disease or disorder is selected from the group consisting of gangrene, diabetic vasculopathy, ischemic bowel disease, thrombosis, diabetic retinopathy and diabetic nephropathy.

162. (Previously Presented) The method of claim 157, wherein said autoimmune disease or disorder is selected from the group consisting of chronic rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease, polyarteritis nodosa, polymyositis/dermatomyositis, Sjogren's syndrome, Bechet's disease, multiple sclerosis, autoimmune diabetes, Hashimoto's disease, psoriasis, primary myxedema, pernicious anemia, myasthenia gravis, chronic active hepatitis, autoimmune

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

hemolytic anemia, idiopathic thrombocytopenic purpura, uveitis, vasculitides and heparin induced thrombocytopenia.

163. (Previously Presented) The method of claim 157, wherein said inflammatory glandular disease or disorder is selected from the group consisting of pancreatic disease or disorder, Type I diabetes, thyroid disease or disorder, Graves' disease or disorder, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome.

164. (Previously Presented) The method of claim 157, wherein said inflammatory gastrointestinal disease or disorder is selected from the group consisting of colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, an ulcer, a skin ulcer, a bed sore, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer and a gastrointestinal ulcer.

165. (Previously Presented) The method of claim 157, wherein said inflammatory cutaneous disease or disorder is selected from the group consisting of acne, autoimmune bullous skin disease or disorder, pemphigus vulgaris, bullous pemphigoid, pemphigus foliaceus, contact dermatitis and drug eruption.

166. (Previously Presented) The method of claim 157, wherein said inflammatory hepatic disease or disorder is selected from the group consisting of autoimmune hepatitis, hepatic cirrhosis, and biliary cirrhosis.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

167. (Previously Presented) The method of claim 157, wherein said inflammatory neurological disease or disorder is selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease, myasthenia gravis, motor neuropathy, Guillain-Barre syndrome, autoimmune neuropathy, Lambert-Eaton myasthenic syndrome, paraneoplastic neurological disease or disorder, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, progressive cerebellar atrophy, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, autoimmune polyendocrinopathy, dysimmune neuropathy, acquired neuromyotonia, arthrogryposis multiplex, Huntington's disease, AIDS associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis, stroke, an inflammatory retinal disease or disorder, an inflammatory ocular disease or disorder, optic neuritis, spongiform encephalopathy, migraine, headache, cluster headache, and stiff-man syndrome.

168. (Previously Presented) The method of claim 157, wherein said inflammatory connective tissue disease or disorder is selected from the group consisting of autoimmune myositis, primary Sjogren's syndrome, smooth muscle autoimmune disease or disorder, myositis, tendinitis, a ligament inflammation, chondritis, a joint inflammation, a synovial inflammation, carpal tunnel syndrome, arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, a skeletal inflammation, an autoimmune ear disease or disorder, and an autoimmune disease or disorder of the inner ear.

169. (Previously Presented) The method of claim 157, wherein said inflammatory renal disease or disorder is autoimmune interstitial nephritis and/or renal cancer.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

170. (Previously Presented) The method of claim 157, wherein said inflammatory reproductive disease or disorder is repeated fetal loss, ovarian cyst, or a menstruation associated disease or disorder.

171. (Previously Presented) The method of claim 157, wherein said inflammatory systemic disease or disorder is selected from the group consisting of systemic lupus erythematosus, systemic sclerosis, septic shock, toxic shock syndrome, and cachexia.

172. (Previously Presented) The method of claim 157, wherein said infectious disease or disorder is selected from the group consisting of a chronic infectious disease or disorder, a subacute infectious disease or disorder, an acute infectious disease or disorder, a viral disease or disorder, a bacterial disease or disorder, a protozoan disease or disorder, a parasitic disease or disorder, a fungal disease or disorder, a mycoplasma disease or disorder, gangrene, sepsis, a prion disease or disorder, influenza, tuberculosis, malaria, acquired immunodeficiency syndrome, and severe acute respiratory syndrome.

173. (Previously Presented) The method of claim 157, wherein said inflammatory transplantation-related disease or disorder is selected from the group consisting of graft rejection, chronic graft rejection, subacute graft rejection, acute graft rejection hyperacute graft rejection, and graft versus host disease or disorder.

174. (Previously Presented) The method of claim 173, wherein said implant is selected from the group consisting of a prosthetic implant, a breast implant, a silicone implant, a dental implant, a penile implant, a cardiac implant, an artificial joint, a bone fracture repair device, a bone replacement implant, a drug delivery

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

implant, a catheter, a pacemaker, an artificial heart, an artificial heart valve, a drug release implant, an electrode, and a respirator tube.

175. (Previously Presented) The method of claim 157, wherein said inflammatory tumor is selected from the group consisting of a malignant tumor, a benign tumor, a solid tumor, a metastatic tumor and a non-solid tumor.

176. (Previously Presented) The method of claim 157, wherein said inflammatory pulmonary disease or disorder is selected from the group consisting of asthma, allergic asthma, emphysema, chronic obstructive pulmonary disease or disorder, sarcoidosis and bronchitis.

177. (Previously Presented) The method of claim 140, further comprising administering to said subject a therapeutically effective amount of at least one additional compound capable of treating or preventing said inflammation.

178. (Previously Presented) The method of claim 177, wherein said at least one additional compound is selected from the group consisting of a HMGCoA reductase inhibitor (a statin), a mucosal adjuvant, a corticosteroid, a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, an analgesic, a growth factor, a toxin, a HSP, a Beta-2-glycoprotein I, a cholesteryl ester transfer protein (CETP) inhibitor, a peroxisome proliferative activated receptor (PPAR) agonist, an anti-atherosclerosis drug, an anti-proliferative agent, ezetimide, nicotinic acid, a squalen inhibitor, an ApoE Milano, and any derivative and analog thereof.

179-192. (Canceled)

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510


193. (Currently Amended) The method of claim 151, wherein:

each of A_1 and A_2 is $CR''R'''$;

each of $B_1, B_2 \dots B_n$ is oxygen;

X_1 is a saturated hydrocarbon said general formula II, whereas Z is hydrogen;

X_2 is a saturated hydrocarbon having said general Formula II, whereas said Z



Y is ~~phosphoryl~~phosphoryl choline.

194. (Currently Amended) The method of claim 193, wherein:

X_1 is said saturated hydrocarbon said general formula II, whereas Z is hydrogen and m equals ~~154~~6; and

X_2 is a saturated hydrocarbon having said general Formula II, whereas m equals ~~3~~4.

195. (Previously Presented) The method of claim 194, wherein each of $R_1, R'_1, R_2, \dots R_{n-1}, R_n, R'_n$, each of R'' and R''' and each of $R_a, R'_a, R_b, R'_b, \dots R_{m-1}, R'_m-1, R_m$ and R'_m is hydrogen.


196. (Previously Presented) The method of claim 195, wherein C_2 is a chiral carbon atom which has a S-configuration or a R-configuration.

197. (Currently Amended) The method of claim 195, wherein said compound is selected from the group consisting of 1-Hexadecyl-2-(~~54~~'-Carboxy-butyl)-sn-glycero-3-phosphocholine and 3-Hexadecyl-2-(~~54~~'-Carboxy-butyl)-sn-glycero-1-phosphocholine.


In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

198. (Currently Amended) The method of claim 195, wherein said compound has the formula:




199. (Currently Amended) The method of claim 195, wherein said compound has the formula:



200. (New) A compound having the general formula I:

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510



Formula I

wherein:

n is an integer of 1-6, whereas if n=1, C_n, B_n, R_n, and Y are absent;

each of B₁, B₂, ...B_{n-1} and B_n is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, whereby each of said nitrogen, phosphorus and silicon is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;


each of A₁, A₂, ...A_{n-1} and A_n is independently selected from the group consisting of CR''R''', C=O and C=S, whereas when n=3, A₂ is CR''R''';

Y is selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biphosphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine and phosphoglycerol; and

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

each of X_1, X_2, \dots, X_{n-1} is independently a saturated or unsaturated hydrocarbon having the general formula II:




Formula II

wherein:

m is an integer of 1-26; and

Z is selected from the group consisting of:



whereas:

W is selected from the group consisting of oxygen, sulfur, nitrogen and phosphorus, whereby each of said nitrogen and phosphorus is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo; and

in at least one of X_1, X_2, \dots, X_{n-1} , Z is not hydrogen,

wherein if $n=3$, X_2 comprises a Z different than hydrogen; and

Y is selected from the group consisting of phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol,

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biphosphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine and phosphoglycerol;

and wherein:

each of $R_1, R'_1, R_2, \dots, R_{n-1}, R_n, R'_n$, each of R'' and R''' and each of $R_a, R'_a, R_b, R'_b, \dots, R_{m-1}, R'_m, R_m$ and R'_m is independently selected from the group consisting of hydrogen, a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of $R_1, R'_1, R_2, \dots, R_{n-1}, R_n$ and R'_n and/or at least two of $R_a, R'_a, R_b, R'_b, \dots, R_{m-1}, R'_m, R_m$ and R'_m form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring; and

each of $C_1, C_2, \dots, C_{n-1}, C_n$, and each of C_a, C_b, \dots, C_{m-1} and C_m is a chiral or non-chiral carbon atom, whereby each chiral carbon atom has a S-configuration and/or a R-configuration,

a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate thereof.

201. (New) The compound of claim 200, wherein at least one of A_1, A_2, \dots and A_{n-1} is $CR''R'''$.

202. (New) The compound of claim 201 wherein at least one of said at least one of A_1, A_2, \dots and A_{n-1} is linked to a X_1, X_2, \dots or X_{n-1} which comprises a Z different than hydrogen.

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

203. (New) The compound of claim 200, wherein n equals 3, and X₂

comprises a Z selected from the group consisting of $\begin{array}{c} \text{OR}'' \\ | \\ \text{W}=\text{C} \\ | \end{array}$ and $\begin{array}{c} \text{WR}'' \\ | \\ -\text{CH} \\ | \\ \text{WR}''' \end{array}$.

204. (New) The compound of claim 203, wherein W is oxygen and each of R'' and R''' is independently selected from the group consisting of hydrogen and alkyl.

205. (New) The compound of claim 200, wherein n equals 1.

206. (New) The compound of claim 205, wherein at least one of R₁ and R'₁ is a phosphate or a phosphonate.

207. (New) The compound of claim 200, wherein n equals 5 or 6 and at least one of R₁, R'₁ and at least one of R_n and R'_n form at least one heteroalicyclic ring.

208. (New) The compound of claim 207, wherein said at least one heteroalicyclic ring is a monosaccharide ring.

209. (New) A pharmaceutical composition comprising, as an active ingredient, the compound of claim 200 and a pharmaceutically acceptable carrier.

210. (New) The pharmaceutical composition of claim 209, packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment or prevention of an inflammation associated with an endogenous oxidized lipid.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

211. (New) The pharmaceutical composition of claim 210, wherein said inflammation is associated with a disease or disorder selected from the group consisting of an idiopathic inflammatory disease or disorder, a chronic inflammatory disease or disorder, an acute inflammatory disease or disorder, an autoimmune disease or disorder, an infectious disease or disorder, an inflammatory malignant disease or disorder, an inflammatory transplantation-related disease or disorder, an inflammatory degenerative disease or disorder, a disease or disorder associated with a hypersensitivity, an inflammatory cardiovascular disease or disorder, an inflammatory cerebrovascular disease or disorder, a peripheral vascular disease or disorder, an inflammatory glandular disease or disorder, an inflammatory gastrointestinal disease or disorder, an inflammatory cutaneous disease or disorder, an inflammatory hepatic disease or disorder, an inflammatory neurological disease or disorder, an inflammatory musculo-skeletal disease or disorder, an inflammatory renal disease or disorder, an inflammatory reproductive disease or disorder, an inflammatory systemic disease or disorder, an inflammatory connective tissue disease or disorder, an inflammatory tumor, necrosis, an inflammatory implant-related disease or disorder, an inflammatory aging process, an immunodeficiency disease or disorder, a proliferative disease or disorder and an inflammatory pulmonary disease or disorder.

212. (New) The pharmaceutical composition of claim 209, further comprising at least one additional compound capable of treating or preventing an inflammation associated with an oxidized lipid.

213. (New) The pharmaceutical composition of claim 212, wherein said at least one additional compound is selected from the group consisting of a HMGCoA reductase inhibitor (a statin), a mucosal adjuvant, a corticosteroid, a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, an analgesic, a growth

In re Application of: Dror HARATS et al
 Serial No.: 10/567,543
 Filed: April 25, 2008
 Office Action Mailing Date: June 15, 2010


Examiner: Rei Tsang Shiao
 Group Art Unit: 1628
 Attorney Docket: 31532
 Confirmation No.: 8510

factor, a toxin, a HSP, a Beta-2-glycoprotein I, a cholesteryl ester transfer protein (CETP) inhibitor, a perioxosome proliferative activated receptor (PPAR) agonist, an anti-atherosclerosis drug, an anti-proliferative agent, ezetimide, nicotinic acid, a squalen inhibitor, an ApoE Milano, and any derivative and analog thereof.

214. (New) The pharmaceutical composition of claim 209, wherein at least one of A_1 , A_2 , ... and A_{n-1} is $CR''R'''$.

215. (New) The pharmaceutical composition of claim 214, wherein at least one of said at least one of A_1 , A_2 , ... and A_{n-1} is linked to a X_1 , X_2 ... or X_{n-1} which comprises a Z different than hydrogen.

216. (New) The pharmaceutical composition of claim 209, wherein n equals 3, and X_2 comprises a Z selected from the group consisting of



217. (New) The pharmaceutical composition of claim 216, wherein W is oxygen and each of R'' and R''' is independently selected from the group consisting of hydrogen and alkyl.

218. (New) The pharmaceutical composition of claim 209, wherein n equals 1.

219. (New) The pharmaceutical composition of claim 218, wherein at least one of R_1 and R'_1 is a phosphate or a phosphonate.

In re Application of: Dror HARATS et al
Serial No.: 10/567,543
Filed: April 25, 2008
Office Action Mailing Date: June 15, 2010

Examiner: Rei Tsang Shiao
Group Art Unit: 1628
Attorney Docket: 31532
Confirmation No.: 8510

220. (New) The pharmaceutical composition of claim 209, wherein n equals 5 or 6 and at least one of R_1 , R'_1 and at least one of R_n and R'_n form at least one heteroalicyclic ring.

221. (New) The pharmaceutical composition of claim 220, wherein said at least one heteroalicyclic ring is a monosaccharide ring.